CRSP CRISPR Therapeutics
- 56.240
- +1.680+3.08%
- 56.230
- -0.010-0.02%
CRISPR Therapeutics News
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director George Simeon
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Treco Douglas A
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director High Katherine A
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Greene John
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Mahatme Sandesh
CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Rommel Christian
CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Mahatme Sandesh
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Patel Naimish
CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Patel Naimish
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne
CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Bruno Julianne
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 10-Q: Quarterly report
CRISPR Therapeutics | 8-K: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
CRISPR Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Capital International Investors(10.2%)
Analysis
Price Target
No Data
